Interim Report of BB BIOTECH AG as of June 30, 2010
News | 29 July 2010
Valuation of biotechnology companies at historic lows In its Interim Report, BB BIOTECH looked back on a difficult first half-year period for 2010. ...
Click on the link to read the full article at MarketWatch
(This link will open in a new window)
- GlaxoSmithKline’s Avandia still available in UK, despite MHRA call for its suspension
- Israel relaxes restrictions on medical marijuana; scientists develop new HIV/AIDS treatment
- Tough road ahead for some generics after USA’s Federal Circuit Patent Use Code decisions
- Bausch & Lomb moves to acquire Miochol-E from Novartis as required by US competition authority
- German drug price curbs will hamper orphan drug development, says BIO Deutschland
